URGENT: This Altcoin Opportunity Won’t Wait – Act Now

It’s here. This is the moment we’ve been waiting for. The next 3-6 months in crypto will be absolutely life-changing for those who are prepared. Why? Because altcoin prices are about to explode.

Joakim Wijkstrom net worth and biography

Joakim Wijkstrom Biography and Net Worth

CMO of Vanda Pharmaceuticals

Kim Wijkstrom serves as our SVP/Chief Marketing Officer since August 2019. Prior to joining Vanda, Mr. Wijkstrom served as SVP/CMO at Perry Ellis International (PERY), and most recently at OneMain Financial (OMF). Prior to that, Mr. Wijkstrom held a variety of leadership roles at advertising agencies (TBWA Chiat Day, BBDO, Crispin Porter + Bogusky) developing marketing strategies with clients including Apple, Absolut vodka, Activision/Guitar Hero, Nextel, and Volkswagen. Before this, Mr. Wijkstrom received his BA in Art History from Georgetown University, and his MBA in Marketing from New York University. He is also a recipient of the Solomon R. Guggenheim Foundation fellowship for studies in museum administration at the Peggy Guggenheim Collection in Venice, and a Marcus Wallenberg Foundation Scholarship for studies in international business.

What is Joakim Wijkstrom's net worth?: The estimated net worth of Joakim Wijkstrom is at least $517,862.80 as of August 21st, 2023. Mr. Wijkstrom owns 113,816 shares of Vanda Pharmaceuticals stock worth more than $517,863 as of December 18th. This net worth estimate does not reflect any other investments that Mr. Wijkstrom may own. Additionally, Mr. Wijkstrom receives a salary of $846,330.00 as CMO at Vanda Pharmaceuticals. Learn More about Joakim Wijkstrom's net worth.
How old is Joakim Wijkstrom?: Mr. Wijkstrom is currently 58 years old. There are 4 older executives and no younger executives at Vanda Pharmaceuticals. The oldest executive at Vanda Pharmaceuticals is Dr. Mihael H. Polymeropoulos M.D., Founder, President, CEO & Chairman of The Board, who is 64 years old. Learn More on Joakim Wijkstrom's age.
What is Joakim Wijkstrom's salary?: As the CMO of Vanda Pharmaceuticals Inc., Mr. Wijkstrom earns $846,330.00 per year. There are 3 executives that earn more than Mr. Wijkstrom. The highest earning executive at Vanda Pharmaceuticals is Dr. Mihael H. Polymeropoulos M.D., Founder, President, CEO & Chairman of The Board, who commands a salary of $1,920,000.00 per year. Learn More on Joakim Wijkstrom's salary.
How do I contact Joakim Wijkstrom?: The corporate mailing address for Mr. Wijkstrom and other Vanda Pharmaceuticals executives is 2200 PENNSYLVANIA AVENUE NW SUITE 300 E, WASHINGTON DC, 20037. Vanda Pharmaceuticals can also be reached via phone at (202) 734-3400 and via email at [email protected]. Learn More on Joakim Wijkstrom's contact information.
Has Joakim Wijkstrom been buying or selling shares of Vanda Pharmaceuticals?: Joakim Wijkstrom has not been actively trading shares of Vanda Pharmaceuticals in the last ninety days. Most recently, Joakim Wijkstrom sold 3,724 shares of the business's stock in a transaction on Monday, August 21st. The shares were sold at an average price of $5.84, for a transaction totalling $21,748.16. Following the completion of the sale, the chief marketing officer now directly owns 113,816 shares of the company's stock, valued at $664,685.44. Learn More on Joakim Wijkstrom's trading history.
Who are Vanda Pharmaceuticals' active insiders?: Vanda Pharmaceuticals' insider roster includes Phaedra Chrousos (Director), Aranthan Jones, II (Insider), Stephen Mitchell (Director), Kevin Moran (CFO), Mihael Polymeropoulos (CEO), and Joakim Wijkstrom (CMO). Learn More on Vanda Pharmaceuticals' active insiders.
Are insiders buying or selling shares of Vanda Pharmaceuticals?: In the last twelve months, insiders at the biopharmaceutical company sold shares 2 times. They sold a total of 7,251 shares worth more than $39,175.92. The most recent insider tranaction occured on November, 14th when Director Stephen Ray Mitchell sold 5,000 shares worth more than $25,850.00. Insiders at Vanda Pharmaceuticals own 8.9% of the company. Learn More about insider trades at Vanda Pharmaceuticals.
Information on this page was last updated on 11/14/2024.

Joakim Wijkstrom Insider Trading History at Vanda Pharmaceuticals

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
8/21/2023	Sell	3,724	$5.84	$21,748.16	113,816
3/2/2023	Sell	7,720	$6.23	$48,095.60	121,653
8/22/2022	Sell	3,605	$10.27	$37,023.35	96,673
3/2/2022	Sell	6,974	$11.19	$78,039.06
8/20/2021	Sell	3,650	$15.39	$56,173.50
8/20/2020	Sell	3,710	$11.08	$41,106.80	56,290

Joakim Wijkstrom Buying and Selling Activity at Vanda Pharmaceuticals

Vanda Pharmaceuticals Company Overview

Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company's marketed products include HETLIOZ to treat non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia. Its pipeline products include HETLIOZ (tasimelteon) to treat jet lag disorder, insomnia, delayed sleep phase disorder, sleep disturbances in autism spectrum disorder, and pediatric Non-24; Fanapt (iloperidone) for the treatment of bipolar I disorder and Parkinson's disease psychosis, as well as a long acting injectable (LAI) formulation to treat schizophrenia; and Tradipitant (VLY-686), a small molecule neurokinin-1 receptor (NK-1R) antagonist to treat gastroparesis, motion sickness, atopic dermatitis, and COVID-19 pneumonia. The company's pipeline products also include VTR-297, a small molecule histone deacetylase inhibitor to treat hematologic malignancies and with potential use as a treatment for various oncology indications; VQW-765, a small molecule nicotinic acetylcholine receptor partial agonist to treat performance anxiety and psychiatric disorders; VHX-896, an active metabolite of iloperidone; and antisense oligonucleotide molecules. In addition, it offers a portfolio of cystic fibrosis transmembrane conductance regulator activators and inhibitors that include VSJ-110 for the treatment of dry eye and ocular inflammation; and VPO-227 for the treatment of secretory diarrhea disorders comprising cholera. Vanda Pharmaceuticals Inc. was incorporated in 2002 and is headquartered in Washington, the District of Columbia.

Today's Range

Now: $4.55

$4.49

$4.80

50 Day Range

MA: $4.85

$4.41

$5.46

2 Week Range

Now: $4.55

$3.46

$6.75

Volume

675,127 shs

Average Volume

1,239,837 shs

Market Capitalization

$265.30 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.76

URGENT: This Altcoin Opportunity Won’t Wait – Act Now

From Crypto Swap Profits | Ad

It’s here. This is the moment we’ve been waiting for. The next 3-6 months in crypto will be absolutely life-changing for those who are prepared. Why? Because altcoin prices are about to explode.

>> Register for the Workshop Now

Joakim Wijkstrom Biography and Net Worth

What is Joakim Wijkstrom's net worth?

How old is Joakim Wijkstrom?

What is Joakim Wijkstrom's salary?

How do I contact Joakim Wijkstrom?

Has Joakim Wijkstrom been buying or selling shares of Vanda Pharmaceuticals?

Who are Vanda Pharmaceuticals' active insiders?

Are insiders buying or selling shares of Vanda Pharmaceuticals?